ArticleCurrent therapeutic research, clinical and experimental2026
As-Needed Medication Use for Agitation Across Valproic Acid Formulations.
Article in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacokinetic differences between immediate-, delayed- and extended-release (IR, DR, ER) formulations of valproic acid (VPA) may impact therapeutic outcomes. As-needed, pro re nata (PRN) medications may serve as proxies for scheduled medication effectiveness for symptom management. This study compared the number of PRN doses of benzodiazepines and antipsychotics for agitation between VPA formulations. Methods: A retrospective review was conducted for patients with bipolar I or schizoaffective disorder who received three or more days of VPA (IR, DR, ER) doses as maintenance therapy. The primary outcome was the difference in average daily number of PRN benzodiazepine and/or antipsychotic doses for agitation across formulations. The secondary outcome included differences in VPA total daily dose (TDD) across formulations. Descriptive statistics, ANOVA, and hierarchical multiple regression analyses were used for comparisons. Results: A total of 150 patients were included (59% male, 55% Caucasian). The VPA formulation was significantly associated with the average daily PRN antipsychotic and/or benzodiazepine doses, as well as antipsychotic alone, after adjusting for potential confounders (age, sex, race, psychiatry unit, average VPA total daily dose). Conclusion: The significant difference in the number of PRN benzodiazepine and/or antipsychotic doses administered for agitation among the different formulations of VPA may suggest differences in symptom control. Further investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.